A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-06-15
Summary
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Conditions
- Non-small Cell Lung Cancer
- Gastric Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Bladder Urothelial Carcinoma
- Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Renal Cell Carcinoma
- Cholangiocarcinoma
- Pancreatic Cancer
- Other Solid Tumors
Interventions
- DRUG
-
CDX-585
CDX-585 is administered by infusion every 2 weeks
Sponsors & Collaborators
-
Celldex Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-11
- Primary Completion
- 2025-05-21
- Completion
- 2025-05-21
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
NCT00816400 ·Status: COMPLETED ·Phase: PHASE1
-
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
NCT05695898 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT03212404 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT00709462 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers For Immune Checkpoint Inhibitors
NCT04204434 ·Status: COMPLETED
-
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
NCT03538028 ·Status: COMPLETED ·Phase: PHASE1
-
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877 ·Status: COMPLETED ·Phase: PHASE1
-
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
NCT03030001 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
NCT05808634 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
NCT04172454 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
NCT02722954 ·Status: COMPLETED ·Phase: PHASE1
-
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04958434 ·Status: TERMINATED ·Phase: PHASE1
-
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
NCT07158918 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01075464 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
NCT03588650 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01375842 ·Status: COMPLETED ·Phase: PHASE1
-
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035 ·Status: RECRUITING ·Phase: PHASE1
-
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
NCT03513952 ·Status: COMPLETED ·Phase: PHASE2
-
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
NCT02565758 ·Status: COMPLETED ·Phase: PHASE1
-
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05102214 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
NCT02775851 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
NCT04580485 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
NCT02720484 ·Status: TERMINATED ·Phase: PHASE2